Cargando…

Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer’s BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study

INTRODUCTION: Inadequate vaccine response is a common concern among healthcare workers at the frontlines of the COVID-19 pandemic. We aimed to investigate if healthcare workers with history of weak immune response to HBV vaccination are more likely to have weak responses against the BioNTech/Pfizer’...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwamoto, Momoko, Ukimura, Akira, Ogawa, Taku, Kawanishi, Fumiko, Osaka, Naofumi, Kubota, Mari, Mori, Tatsuhiko, Sawamura, Ritsuko, Nishihara, Masami, Suzuki, Tomio, Uchiyama, Kazuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109930/ https://www.ncbi.nlm.nih.gov/pubmed/35576209 http://dx.doi.org/10.1371/journal.pone.0268529

Ejemplares similares

Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine
por: Zappa, Martina, et al.
Publicado: (2021)

Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
por: Landsberg, Hannah E., et al.
Publicado: (2022)

MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination
por: Obata, Shota, et al.
Publicado: (2021)

Recurrent MRI-documented myocarditis following Pfizer-BioNTech SARS-CoV-2 vaccination
por: Bucur, Philip, et al.
Publicado: (2022)

A child with crescentic glomerulonephritis following SARS-CoV-2 mRNA (Pfizer-BioNTech) vaccination
por: Kim, Sujeong, et al.
Publicado: (2022)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2021)

Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review
por: Reynolds, Lia, et al.
Publicado: (2023)

Cerebral Venous Thrombosis after SARS-CoV-2 Infection and Pfizer-BioNTech Vaccination against COVID-19
por: Nicolardi, Martina, et al.
Publicado: (2022)

Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination
por: Algaissi, Abdullah, et al.
Publicado: (2022)

A Case of Purpura Annularis Telangiectodes of Majocchi after Anti-SARS-CoV-2 Pfizer-BioNTech Vaccine: Is There an Association?
por: Ambrogio, Francesca, et al.
Publicado: (2022)

Recurrent giant cellulitis-like Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine
por: Hirt, Penelope, et al.
Publicado: (2023)

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
por: Korth, Johannes, et al.
Publicado: (2021)

Unusual Case of Painful Glossitis and Xerostomia Following Vaccination with Pfizer-BioNTech SARS-CoV-2 (BNT162b2)
por: Tan, Elina, et al.
Publicado: (2022)

De Novo Minimal Change Disease following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor
por: Marinaki, Smaragdi, et al.
Publicado: (2021)

Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status
por: Eyre, David W., et al.
Publicado: (2021)

Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naïve and previously infected by SARS-CoV-2
por: Chong-Valbuena, Andrea, et al.
Publicado: (2022)

New-onset pediatric nephrotic syndrome following Pfizer-BioNTech SARS-CoV-2 vaccination: a case report and literature review
por: Nakazawa, Eriko, et al.
Publicado: (2021)

Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty(Ⓡ)])
por: Ando, Masaru, et al.
Publicado: (2022)

Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination
por: Kim, Namhee, et al.
Publicado: (2021)

Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster
por: da Silva, Almir Ribeiro, et al.
Publicado: (2022)

Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
por: Kobashi, Yurie, et al.
Publicado: (2022)

Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants
por: Seki, Yohei, et al.
Publicado: (2022)

Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis
por: Yau, Kevin, et al.
Publicado: (2022)

Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients
por: Kaiser, Robert A., et al.
Publicado: (2021)

Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine
por: Basile, Kerri, et al.
Publicado: (2022)

Humoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experience
por: Sánchez-Zapardiel, Elena, et al.
Publicado: (2022)

Multiple Evanescent White Dot Syndrome following BioNTech SARS-CoV2 mRNA vaccination
por: Ninet, L., et al.
Publicado: (2022)

Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8(+) T cell responses post SARS-CoV-2 infection
por: Gao, Fei, et al.
Publicado: (2023)

Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile
por: Díaz-Dinamarca, Diego A., et al.
Publicado: (2023)

A definite case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) induced by administration of the Pfizer/BioNTech BNT162b2 vaccine for SARS-CoV2
por: Schroeder, Jan Walter, et al.
Publicado: (2022)

The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster
por: Wolszczak Biedrzycka, Blanka, et al.
Publicado: (2022)

Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans
por: Vályi-Nagy, István, et al.
Publicado: (2021)

The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine
por: Farid, Eman, et al.
Publicado: (2022)

Tachycardia as an undescribed adverse effect to the Comirnaty© vaccine (BNT162b2 Pfizer-BioNTech Covid-19 vaccine): Description of 3 cases with a history of SARS-CoV-2 disease()
por: Marco García, M. Teresa, et al.
Publicado: (2022)

The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMIRNATY vaccine (Pfizer/BioNTech)
por: Andries, Jessica, et al.
Publicado: (2022)

Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans
por: Galvan, Veronica, et al.
Publicado: (2021)

Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel
por: Saciuk, Yaki, et al.
Publicado: (2022)

Skin testing with Pfizer SARS-CoV-2 vaccine and PEG 2000
por: Vieira, João, et al.
Publicado: (2021)

Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients
por: Miele, Monica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sgmr72918jmo6vk4i0ec565i92